You are here
Daniel Press, M.M.Sc.
Dr. Press is the clinical director of the Berenson-Allen Center for Noninvasive Brain Stimulation and the medical director for the Cognitive Neurology Unit at Beth Israel Deaconess Medical Center (BIDMC). He is also an associate professor of neurology at Harvard Medical School (HMS).
Dr. Press earned his undergraduate degree from the University of Pennsylvania and his medical degree from the University of Connecticut School of Medicine. He received a scholarship to spend one year at the National Institutes of Health (NIH) through the Howard Hughes Medical Institute-NIH Research Scholars Program, where he pursued research in the Clinical Brain Disorders Branch of the National Institute of Mental Health. Dr. Press completed a neurology residency in the Harvard Longwood Neurology Training Program and a fellowship in cognitive neurology at BIDMC. He received a master of medical sciences degree from HMS through the Harvard-MIT Clinical Investigator Training Program.
Dr. Press is a leader in education, research, and clinical treatment, with a focus on diseases like Alzheimer’s disease and Parkinson’s disease. His research concentrates on studying the effects of brain disease on one’s ability to learn new motor skills, and how those effects can be reversed. In collaboration with motor control experts from the Harvard School of Engineering and Applied Sciences, Dr. Press has developed a model for how motor learning may be impaired in Alzheimer’s disease. Using this model, he has begun testing whether noninvasive brain stimulation to specific brain areas can treat this deficit.
In his role as clinical director for the Berenson-Allen Center, Dr. Press and his team treat patients with neuropsychiatric conditions, including medication-resistant depression. This team has performed over 10,000 transcranial magnetic stimulation (TMS) treatments to more than 200 patients in the last 10 years, helping them to achieve and maintain more normal lives. He also has directed a medical education course to help train others from around the world in the clinical aspects of non-invasive brain stimulation.
Dr. Press is a member of a number of medical societies and serves on medical advisory boards for both the Massachusetts Registry of Motor Vehicles and the Massachusetts branch of the Alzheimer’s Association. He has authored or co-authored more than 50 scientific articles, chapters, and reviews, and has written editorials for leading medical journals including Neurology and The New England Journal of Medicine.
Jonathan Downar, M.D., Ph.D., FRCPC
Dr. Downar serves as the Director of the MRI-Guided rTMS Clinic at University Health Network, and also holds the position of Scientist at the Toronto Western Research Institute. He completed a BSc in biology at McGill University, followed by a Ph.D. in neuroimaging at the University of Toronto with Dr. Karen Davis, before obtaining his medical degree from the University of Calgary in 2005. He then returned to Toronto for his psychiatry residency training, during which he also completed a research fellowship in neuroeconomics with Dr. Read Montague at Baylor College of Medicine.
Dr. Downar joined the Department of Psychiatry at UHN on completion of his residency in 2010. Shortly thereafter, he established the MRI-Guided rTMS Clinic, with a mandate to accept referrals from the community as a clinical resource, while simultaneously conducting translational research into improving the efficacy, cost, access, and range of indications for non-invasive brain stimulation in psychiatric illness. The UHN clinic now includes 4 treatment suites, treats volumes of 50-60 patients daily, and receives >500 referrals/year. The UHN clinic works in close collaboration with Drs. Daskalakis and Blumberger at the Temerty Centre at CAMH.
Dr. Downar's research work focuses on translating advances in basic neuroimaging and neuroscience research into improvements in the efficacy, capacity, and cost of rTMS. His lab also seeks to identify better targets for rTMS across a wider range of conditions and to identify neuroimaging biomarkers to predict the best treatment parameters for individual patients presenting for treatment. He currently holds an operating grant from CIHR as well as peer-reviewed funding from Brain Canada, the Klarman Foundation, and the Edgestone Foundation. His work has been published in Biological Psychiatry, Neuropsychopharmacology, Brain Stimulation, and Nature Neuroscience.
Paul FitzgeraldDr. Fitzgerald has been involved in the development, evaluation and clinical implementation of new treatments for mental health disorders for 2 decades. He pioneered the use of TMS in Australia and is internationally renown as a leader in the field of brain stimulation and device-based treatments in psychiatry. He has published over 300 peer-reviewed journal articles and book chapters and conducted an extensive series of research studies and clinical trials. He is currently continuing this research and clinical work at the Epworth with studies/trials underway or planned in depression, OCD, Alzheimer's disease, and PTSD.
Abraham Zangen, Ph.D.
Professor Zangen is the Head of the Brain Stimulation and Behavior Lab and the Chair of the PsychoBiology Brain Program at Ben-Gurion University in Israel. His research is directed at identifying and understanding altered neuroplasticity in psychiatric disorders – primarily depression, addiction, and ADHD.
He studies the effects of repeated brain stimulation on markers for neuroplasticity and on behavioral outcomes in animal models for depression and addiction, as well as in psychiatric patients. He has developed with Dr. Yiftach Roth unique deep transcranial magnetic stimulation coils for the treatments of depression, addiction, OCD, and ADHD.
The technology he and Dr. Roth has developed for the treatment of depression was already approved by the FDA and other regulatory bodies, while other versions of the coils they have developed are being tested for their efficacy in other psychiatric and neurological disorders.
His early work in this field led to the establishment of Brainsway, a company that commercializes the technologies he developed with his colleagues.
Professor Zangen has published over 150 peer-reviewed articles, reviews and book chapters. He was rewarded with numerous personal prizes for his scientific achievements, including the Medical Futures Innovation Award in London, the Sieratzki Prize for Advances in Neuroscience and the Juludan Prize at the Technion, and he has received several distinguished research grants including NIH, H2020, and ISF funding.
Paul E. Croarkin, D.O., MSc
Dr. Croarkin is an Associate Professor of Psychiatry and the Division Chair for Child and Adolescent Psychiatry at Mayo Clinic. Dr. Croarkin’s research program focuses on adapting and innovating brain stimulation interventions in children and adolescents. This includes biomarker work to optimize diagnostic practices and the delivery of brain based interventions such as transcranial magnetic stimulation. A central theme focuses on the role of gamma-aminobutyric acid (GABA) and glutamate neurotransmitter systems in early-onset mood disorders with the goal of informing safer and more effective biologic treatments. This research is funded by a variety of industry, federal, and foundation grants. He is the current president of the Clinical TMS Society and is an active member of the annual meeting and research committees.
Colleen A. Hanlon, Ph.D.
Dr. Hanlon is an associate professor in the departments of Psychiatry and Neurosciences at the Medical University of South Carolina. There she leads a clinical neuroscience laboratory dedicated to mapping and modulating dopaminergic fronto-striatal systems that contribute to the cycle of initiation, use, and relapse among multiple substance dependent populations. In 2011 she was honored with an Early Career Investigator award from the National Institute of Drug Abuse. In 2017 her NIH-funded brain stimulation research was highlighted in National Geographic (Sept 2017) and Science Magazine (Sept 2017). She also serves as the Associate Director of the Brain Stimulation Core at MUSC and is the Director of the Advanced TMS Training Course sponsored by the MUSC National Center for Neuromodulation for Rehabilitation.
Dr. Hanlon performed her doctoral research in the Department of Neurobiology at Duke University and did a postdoctoral fellowship with Dr. Linda Porrino in the Department of Physiology and Pharmacology at Wake Forest University School of Medicine. Her doctoral research at Duke University involved functional neuroimaging of cortical-striatal plasticity that occurs in the first few months following a stroke. Here she became interested in fronto-striatal dopamine systems that guide behavior, which led to postdoctoral studies in the Center for the Neurobiology of Addictive Disorders at Wake Forest University.
The majority of her work to date has focused on functional neuroimaging and brain stimulation in cocaine-dependent individuals, tobacco smokers, and alcohol users. She also, however, has had a history of research using functional MRI and TMS to evaluate chronic pain, stroke rehabilitation, Parkinson’s Disease and Tourette Syndrome. In addition to primary clinical research, she also has strong collaborations with several preclinical addiction researchers.
Lauren Valencia, LCSW
Lauren has been with NCHH and the Neuroscience and TMS Treatment Center since 2013 as a Therapist and TMS Coordinator. She has presented and spoken at the Clinical TMS Society Annual Meetings in 2016, 2017, and 2018. In therapy and during TMS sessions Lauren utilizes aspects of CBT, DBT, and Motivational Interviewing to work with patients strengths and develop treatment goals relevant to living a fulfilling life.
Lauren graduated with her Masters of Science in Social Work from the University of Tennessee College Of Social Work in 2013. Prior to becoming an LMSW Lauren received her B.S. in Psychology and Criminology from Florida State University. Lauren's previous experiences include working with patients in the TVHS VA System, Alive Hospice, and Children's Home Society of Florida.
Mark George, M.D.
Dr. George is a world expert in brain stimulation, and depression, and is the editor-in-chief of a new journal he launched with Elsevier in 2008 called, Brain Stimulation: Basic, Translation and Clinical Research in Neuromodulation. He has been continuously funded by NIH and other funding agencies since his fellowships. He has received both a NARSAD Young Investigator and Independent Investigator Award to pursue TMS research in depression. He has received numerous international awards including the NARSAD Klerman Award (2000), NARSAD Falcone Award (2008) and the Lifetime Achievement Award (2007) given by the World Federation of Societies of Biological Psychiatry (WFSBP). In 2009 US News and World Report named him one of 14 ‘medical pioneers who are not holding back’. He is on several editorial review boards and NIH study sections, has published over 400 scientific articles or book chapters, and has written or edited 6 books.
Letizia Leocani, M.D., Ph.D., Professor of Neurology
Dr. Leocani is an Associate professor of Neurology at Vita-Salute San Raffaele University, Neurologist in the Neurorehabilitation Unit of the Neurological Department and supervisor of the Experimental neurophysiology Unit and of Magnetic IntraCerebral Stimulation (MagICS) center - Institute of Experimental Neurology, IRCCS Ospedale San Raffaele.
After her medical degree, she obtained a Ph.D. in Human Physiology and Neurology specialty and she has been Research Fellow at the Human Motor Control Section of the National Institutes of Health in Bethesda-USA. Her fields of interest involve translational validation of electrophysiological (advanced EEG analysis, evoked and cognitive potentials) and structural (optical coherence tomography - OCT) markers of diseases of the central nervous system and of treatment strategies using non-invasive brain stimulation to potentiate the effects of drugs and neurorehabilitation.
Linda L. Carpenter, M.D.
Dr. Carpenter is a Professor of Psychiatry in the Alpert Medical School of Brown University and Chief of the Mood Disorders Program at Butler Hospital. Dr. Carpenter completed her undergraduate degree at the University of Michigan, her MD from the University of Pennsylvania, and internship in internal medicine, a residency program in psychiatry, and a clinical neuroscience research fellowship at Yale University. She joined the faculty at Brown in 1997 and has continued her path as a physician-scientist investigating the neurobiology of, and new treatments for, major depression and other mood and anxiety disorders. She led a 10-year, federally funded translational research program focusing on the development of laboratory biomarkers signaling risk for mood/anxiety disorders, and understanding the impact of early life stress on adult biology. She has also conducted a number of randomized clinical trials sponsored by industry and NIH, investigating investigational drugs and devices for treating depression, including Vagus Nerve Stimulation (VNS), Deep Brain Stimulation (DBS), Transcranial Magnetic Stimulation (TMS) and transcranial Direct Current Stimulation (tDCS). She is the founding Director of the Butler Hospital TMS Clinic and Neuromodulation Research Facility where she treats patients with pharmacoresistant depression and works with a variety of Brown-based research faculty who incorporate noninvasive brain stimulation techniques into their clinical research. Her current research projects involve using imaging and EEG biomarkers to optimize and individually customize TMS therapy for depression.
Kenneth E Goolsby, M.D.
Dr. Goolsby received his medical degree from the Medical College of Georgia. He completed his residency in psychiatry at the William S. Hall Psychiatric Institute and Emory University, and his fellowship in child psychiatry at the William S. Hall Psychiatric Institute.
Dr. Goolsby then established his private psychiatric practice in Gainesville, GA and for the first twenty-seven years provided inpatient and outpatient psychiatric services. In 2014, he changed the focus of his practice to include treatment with Transcranial Magnetic Stimulation. In 2016, he incorporated Theta Burst Stimulation into the services provided by his outpatient practice. Currently, Dr. Goolsby has become a leading provider of Transcranial Magnetic Stimulation in Georgia having provided more than 15,000 TMS and TBS treatments.
In addition to his use of the traditional figure 8 coil, he also has extensive experience with the use of several angulated coils including the B-70 & DB-80, allowing common sites of stimulation to include (R) and (L)DMPFC, and (R) and (L)OFC, in addition to the (R) and (L) DLPFC. In his attempts to optimize patient response to TMS and/or TBS, utilizing different sites of stimulation, and accelerated TMS/TBS treatments, he also has extensive experience in utilizing extended TMS/TBS treatments. To date, he has treated 46 patients with more than 100 of TMS/TBS treatments, including multiple courses of TMS/TBS, or in the same course.
Dr. Goolsby has extended experience utilizing the following FDA approved TMS devices; Neurostar, Magstim, and MagVenture.
Kimberly K Cress, M.D.
Dr. Cress graduated from the University of Texas Health Science Center, San Antonio Medical School. Dr. Cress’ vast experience includes treating patients with treatment refractory depression, anxiety disorders and bipolar disorders at the Mood Disorder Center at Baylor College of Medicine. She was also involved with a variety of clinical trials and a co-author in several journal articles. After finding patients were still struggling with depression and anxiety despite numerous medication trials and/or therapies, Dr. Cress chose to incorporate TMS therapy as a treatment option to help patients regain the quality of life they deserved – without the unwanted side effects. Dr. Cress has treated patients with TMS therapy since April 2010. She has completed Harvard Medical School’s Intensive Course in Transcranial Magnetic Stimulation and Transcranial Direct Current Stimulation, along with completing courses at Duke University in Transcranial Magnetic Stimulation. Now, as Regional Medical Director of Greenbrook TMS Houston, Dr. Cress is at the forefront of the field of TMS and neuromodulation and always seeking opportunities to grow and educate patients and colleagues on TMS.
Michael Fox, M.D., Ph.D.
Dr. Fox is an Associate Professor of Neurology at Harvard Medical School and the Director of the Laboratory for Brain Network Imaging and Modulation. He is Co-Director of the BIDMC Deep Brain Stimulation Program, Associate Director of the Berenson-Allen Center for Noninvasive Brain Stimulation, Assistant Neuroscientist at Massachusetts General Hospital, and a practicing clinical neurologist at Beth Israel Deaconess Medical Center.
Dr. Fox received a bachelor’s degree in Electrical Engineering from the Ohio State University in 2001 and an MD and Ph.D. from Washington University in St. Louis in 2008. Following a medical internship at Barnes Jewish Hospital in St. Louis, he completed his Neurology Residency and Movement Disorders Fellowship at Massachusetts General Hospital and Brigham and Women’s Hospital in Boston. He joined the faculty of Beth Israel Deaconess Medical Center and Harvard Medical School in 2014.
Clinically, Dr. Fox specializes in the use of both invasive and noninvasive brain stimulation for the treatment of neurological disease. His practice includes deep brain stimulation (DBS) for the treatment of Parkinson’s Disease, essential tremor, and dystonia as well as transcranial magnetic stimulation (TMS) for the treatment of medication-refractory depression.
Dr. Fox’s research focuses on the development of new and improved treatments for neuropsychiatric disease based on understanding brain networks and the effects of brain stimulation. His papers have been cited over 21,000 times and he has won numerous awards for his work, including recognition as one of the “World’s Most Influential Scientific Minds” by Thompson-Reuters for the past four years and a finalist for the inaugural Trailblazer Award from the NIH.
Richard J. PITCH, M.D.
Dr. Pitch is a board-certified psychiatrist specializing in treatment-resistant depression. He graduated from Wesleyan University and SUNY-Downstate Medical Center in Brooklyn and completed his residency training and was chief resident at Hillside Hospital/Long Island Jewish Medical Center. He was honored by NAMI (National Alliance for Mental Illness) with the Exemplary Psychiatrist Award. In 2009 he was also certified, with distinction, as a Master Psychopharmacologist by the Neuroscience Education Institute. He has maintained a private practice in outpatient psychiatry since 1995, and currently in full-time private practice at the Family Psychology of Long Island in Oakdale, NY where he also the Medical Director of Oakdale TMS.
Mindy Millman-DiCrosta, CMO
Mindy's experience with TMS and other cutting-edge modalities of treatment come from both a personal and professional standpoint. When her daughter suffered from debilitating anxiety, OCD and later depression, she began a quest for medication-free treatments. Due to the fear of medication, her daughter became the youngest patient covered for TMS in Connecticut after winning an appeal.
Mindy has owned and operated a marketing company for 20 years, helping to take products and services to market and building scalable business solutions with innovative database collection programs. After starting out as a reseller in telecommunications and opening a direct response call center Mindy moved into the modeling and entertainment space and gained expertise in branding and marketing in theat sector securing a 5-year partnership with ELLE Magazine and Hachette Media. Mindy's contacts and expertise lend themselves well to celebrity and charity integration which she hopes will be utilized in mental health via MHSS with the right providers. Mindy has worked with TMS practices in expansion and TMS technology companies in testing marketing campaigns.
Geoffrey Grammer, M.D.
Dr. Grammer serves as Greenbrook's Chief Medical Officer where he develops TMS Therapy treatment protocols and oversees the training of staff physicians and technicians. Dr. Grammer created one of the very first TMS Therapy centers in the United States, and he is valued as a leading practitioner of TMS Therapy by his colleagues.
Aron Tendler, M.D.
Dr. Tendler graduated in 2002 from State University of New York Downstate Medical School in Brooklyn with a distinction in research. From 2002-2004, he trained at Tulane University in Internal Medicine and Psychiatry followed by two years at the University of Chicago in General Psychiatry, where he was the chief resident of the consultation-liaison service and course director for psychosomatic medicine. Dr. Tendler is Board Certified in General Psychiatry, Sleep Medicine and Behavioral Sleep Medicine. In 2006, Dr. Tendler established Advanced Mental Health Care Inc. in Palm Beach County, Florida. Dr. Tendler began using TMS clinically in 2009 for a variety of psychiatric and neurological conditions. Currently, he has three clinical research sites studying the efficacy of Deep TMS for bipolar depression, smoking cessation, PTSD and OCD.
Richard A. Bermudes, M.D.
Dr. Bermudes is Board Certified in Adult Psychiatry and Family Medicine, with 20 years’ experience caring for patients. He founded TMS Health Solutions in 2007, serves as the practice’s Medical Director, and is an expert on TMS practice organization and policy development. With his background as a professor and researcher, he leads the practice in its mission to educate the public and clinicians on both mental health issues and TMS, to continually seek the most advanced treatments, and to actively contribute to the medical community’s knowledge of mental health conditions and therapy efficacy.
He recently wrote and edited “Transcranial Magnetic Stimulation: Clinical Applications for Psychiatric Practice”, a book with key research findings on TMS as well as its potential to be used for other conditions such as OCD, PTSD, Adolescent Depression and mild dementia. He is experienced in treating patients with MDD (Major Depressive Disorder), including Unipolar Depression.
Dr. Bermudes is a caring, collaborative practitioner with a structured, goal-oriented approach to treating mental health conditions. His treatment plans may include TMS, medication management or cognitive therapy.
Monique Black, CEO
Having worked with over thirty-five TMS practices and consulted with over seventy-five TMS thought leaders in the U.S., Monique offers a unique range of clinical, marketing, and business development expertise in TMS. She worked for the device manufacturer, Neuronetics, where she specialized in developing TMS practices in California. Monique then joined TMS Health Solutions, a multi-center TMS practice, where she developed sales and marketing strategies, maximized operational functions and worked hand-in-hand with providers to refine their TMS practices. Monique is an expert at incorporating off-label TMS applications, such as generalized anxiety disorder (GAD), mild cognitive impairment (MCI), and postpartum depression (PPD) into practices.
Anthony T. Barker, B.Eng., Ph.D., FIET, FIPEM, Retired Consultant Clinical Scientist
Dr. Barker recently retired from the U.K. National Health Service after 38 years in the Sheffield Department of Medical Physics and Clinical Engineering. An engineer by training, Dr. Barker’s Ph.D. was on the study of peripheral nerve conduction velocities. During this period he started to investigate nerve stimulation using magnetically induced currents. He continued this work after his Ph.D. and led the group which invented the technique of Transcranial Magnetic Stimulation (TMS), now widely used throughout the world for basic research, diagnosis and therapy. Dr. Barker has an active interest in the public understanding of science and has given many named and public lectures including the Faraday lecture series, the Silvanus P Thomson series, and a Royal Institution Discourse. He is an honorary Professor Associate of the University of Sheffield, a Fellow of the Institution of Engineering and Technology and of the Institute of Physics and Engineering in Medicine. He received the inaugural International Brain Stimulation Award in 2017 for the development of TMS.
Ian A Cook, MD DFAPA
Dr. Cook is a Director of the Los Angeles TMS Institute, Inc., and Professor Emeritus of Psychiatry and Biobehavioral Sciences in UCLA’s David Geffen School of Medicine, where he previously held the Miller Family Endowed Chair in Depression Research, was Director of the UCLA Depression Research & Clinic Program, and was the Founding Director of the UCLA TMS Service. Dr. Cook earned his bachelors degree with high honors from Princeton University and his medical degree from the Yale University School of Medicine. He completed his psychiatry residency training at UCLA's Neuropsychiatric Institute, where he also was an NIMH-funded research fellow, before joining the faculty. Dr. Cook served on the Executive Committee on Practice Guidelines of the American Psychiatric Association and guided the electronic dissemination of their evidence-based guidelines in psychiatry. A board-certified Psychiatrist, he has also served as an examiner for the American Board of Psychiatry and Neurology. His biography is profiled in Who's Who in America, Who's Who in the World, and Best Doctors. He is the author of numerous publications on brain function in mental illness and in aging and holds several dozen patents on biomedical devices and methods.
John P O'Reardon, M.D., DFAPA
Dr. O’Reardon received his medical degree from University College Cork, in Ireland. He initially trained in primary care and is board certified in family medicine in Ireland and the UK. He completed his residency training in psychiatry at the University of Pennsylvania, and subsequently fellowships in psychopharmacology and in cognitive therapy. He was a Van Ameringen fellow at the Beck Institute for Cognitive Therapy and is a founding fellow of the Academy of Cognitive Therapy. Dr. O’Reardon is a Diplomate of the American Board of Psychiatry and Neurology.
Dr. O’Reardon’s clinical and research interests include treatment-resistant mood disorders, the development of novel neuromodulation therapies in psychiatry such as TMS, VNS, tDCS, and deep brain stimulation (DBS) along with cognitive therapy, and the night eating syndrome. He has served as an investigator in numerous clinical trials of therapeutic interventions including medications, cognitive therapy, TMS, VNS, DBS, and tDCS. He was full-time faculty at the University of Pennsylvania for 15 years and attained Associate Professor rank there. He is currently in private practice.
He has made many contributions to the literature in his areas of interest in leading specialty journals including the Archives of General Psychiatry, Biological Psychiatry, Journal of Clinical Psychiatry, and the American Journal of Psychiatry. Has more than 100 peer-reviewed scientific publications. He has been teaching faculty at the APA, Institute of Psychiatric Services and International Society for ECT and Neurostimulation (ISEN), Clinical Transcranial Magnetic Stimulation Society (CTMSS) annual meetings in the area of mood disorders and neuromodulation treatments.
Andrew Leuchter, M.D.
Dr. Leuchter is a Professor of Psychiatry at the Semel Institute for Neuroscience and Human Behavior at UCLA. He also is Director of the Neuromodulation Division and a Senior Research Scientist at the Semel Institute. Dr. Leuchter is a graduate of Stanford University and the Baylor College of Medicine who joined the UCLA faculty in 1986.
An internationally recognized expert on the treatment of mood disorders, Dr. Leuchter directs the Transcranial Magnetic Stimulation (TMS) Service, which performs more than 5,000 treatments each year for patients with depression, pain, and other neuropsychiatric illness. He is leading clinical trials to develop novel neuromodulation technologies for the treatment of depression and Post-Traumatic Stress Disorder (PTSD), including synchronized Transcranial Magnetic Stimulation (sTMS) and Trigeminal Nerve Stimulation (TNS). He also has unique expertise in the development of neurophysiologic biomarkers to inform diagnostic and treatment decisions. A Board-certified electroencephalographer, Dr. Leuchter has shown that changes in brain oscillations early in treatment can be used to select antidepressant treatments that are most likely to benefit an individual patient.
Dr. Leuchter has authored over 150 scientific articles on topics including neuromodulation for the treatment of depression, EEG biomarkers to guide treatment of neuropsychiatric illness, and theories of antidepressant action.
Daniel M. Blumberger, M.D., MD, MSc, FRCPC
Dr. Blumberger completed his medical school training at the University of Toronto where he also completed his residency training in psychiatry. He completed a Research Fellowship in Brain Stimulation and Geriatric Psychiatry at the Centre for Addiction and Mental Health. He is certified as a sub-specialist in Geriatric Psychiatry. He is the Medical Head and Co-Director of the Temerty Centre for Therapeutic Brain Intervention. His research focuses on the use of brain stimulation therapies for refractory psychiatric disorders. His main research focuses on novel treatments and understanding the neurophysiology of treatment-resistant depression across the lifespan. He is the principal investigator or co-investigator on numerous clinical trials using different brain stimulation modalities including magnetic seizure therapy (MST), repetitive transcranial magnetic stimulation (rTMS), deep rTMS and transcranial direct current stimulation (tDCS).
John Rothwell, Ph.D., MA
Dr. Rothwell is a professor of neurophysiology at the Institute of Neurology, Queen Square, London. His main area of interest is transcranial magnetic stimulation and motor control. His group has pioneered the use of the paired-pulse technique (Kujirai et al. 1992), interhemispheric studies (Ferbert et al. 1992). Dr. Rothwell was educated at the University of Cambridge and progressed to a MRC Fellowship. He did his PhD under David Marsden. He became head of the MRC Human Movement and Balance Unit upon the untimely death of David Marsden. He has written over 400 papers and numerous chapters.
Shelly Menolascino, M.D., psychiatrist
As a psychiatrist in full-time private practice for the past 25 years, my practice evolved over the past 5 years to Washington Square Psychiatry & TMS. My expertise has always included treatment-resistant patients with recurrent mood disorders and often comorbid with anxiety problems, so often driven by developmental trauma. Over the past 5 years, we have used advanced diagnostic tools including genetic assays and EEG/QEEG variants.
As the Medical Director of Washington Square Psychiatry & TMS, I serve as Attending TMS Psychiatrist, and as such provide direct supervision to daily TMS patients. Direct supervision, as defined by Medicare, means I am in the office and immediately available to provide assistance to our TMS clinicians/technologists.
Caroll Brammer, M.B.A.
Caroll is the Clinical TMS Director for Carolina Partners in Mental Healthcare, PLLC in Raleigh, North Carolina. Caroll obtained her undergraduate degree from the University of Arkansas and her MBA from Indiana University. She began her medical career working for a Level 1 Trauma Unit as the Trauma Coordinator, then migrated into Neurology. Caroll has a passion for changing the lives of those dealing with medication resistant depression and channeled that into building a TMS program from the ground up. The practice had an 85% remission rate with MRD and treated Mild Cognitive Disorder and Parkinson's Disease off-label with great results. Caroll is excited about the future of TMS and what it could mean for the health and wellbeing of patients with a multitude of psychiatric and neurological indications.
Jessica graduated from Michigan State University in 2016 with her Bachelors of Science in Psychology. She has worked at Greenbrook TMS NeuroHealth Centers as a TMS Technician and Patient Consultant since graduating, furthering her experience in patient care and mental health. Jessica has experience administering TMS with several devices including NeuroStar, BrainsWay, and MagVenture. She has treated patients with a multitude of disorders and has also participated in the BrainsWay H7-Coil dTMS Compared to H1-Coil dTMS with MDD clinical trial. Jessica has since grown passionate for TMS and its clinical capabilities, planning to continue working with TMS in her long-term career path.
Elyssa Sisko, CCRC
Elyssa is the clinical research coordinator for Advanced Mental Health Care in Palm Beach County, FL. She began working with Dr. Tendler as a research assistant and TMS technician after graduating with bachelors in biology from Rollins College. Ms. Sisko has extensive experience administering both rTMS (Magstim & Neurostar) and dTMS (H1, H4, H7, and H9 coils) as well as training others. Elyssa was an operator for the dTMS clinical trial for MDD which gained FDA approval. Additionally, she has experience treating TMS patients affected by Parkinson’s, stroke, multiple sclerosis, bipolar depression, bipolar mania, anxiety, panic, OCD, addiction, depression, PTSD, and chronic pain. Currently, Elyssa Sisko is the clinical research coordinator and rater for dTMS clinical trials for smoking cessation, OCD, PTSD, MDD and Bipolar depression.
Annabel graduated from Northeastern University in 2016 with her bachelors in Behavioral Neuroscience. She has since worked as a TMS Technician at Sandhills Neurologists in North Carolina where she has further developed her passion for providing outstanding medical care to patients in her pursuit to become a Physicians Assistant. Annabel enjoys advocating TMS at its core as a growing tool to aid patients in treating a range of neurological and psychiatric conditions and is dedicated to being a part of the continuing and pioneering study of Neurology.
Kathy Anne Daddario, RN, BSN
Kathy is the TMS Program Coordinator and Nurse Technician at Sheppard Pratt Health System, consistently ranked one of the nation’s top 10 psychiatric hospitals by U.S. News & World Report. For the last 10 years, Kathy has been working as part of the Transcranial Magnetic Stimulation Team at Sheppard under the leadership of Dr. Scott Aaronson, Director of Clinical Research Trials and board director for the CTMSS.
In addition to her role as TMS Program Coordinator, Kathy has also served as Lead Nurse for The Retreat at Sheppard Pratt, a premier psychiatric residential facility. She has a second BS in mass communications and public relations, and experience in program development. Kathy was voted by the Baltimore Magazine as Top Nurse in the category of psychiatry and neurology in 2016.
Martijn Arns, Ph.D.
Dr. Arns graduated in 1998 as a biological psychologist at Radboud University in Nijmegen and received his PhD in 2011 at Utrecht University on the topic of 'EEG-based personalized medicine for ADHD and depression' and is specialized in neurobiological aspects of ADHD and depression. In 2001 he founded Research Institute Brainclinics as an independent research institute, where he further specializes in advancing the understanding of psychiatric disorders through brain imaging (QEEG, ERPs), chronobiology and sleep, Research Domain Criteria (RDoC), which knowledge should aid in a future of personalized medicine in mental health. He is specialized in the development and application of neuromodulation techniques such as neurofeedback in the treatment of ADHD and rTMS in the treatment of depression and OCD. He supervises a team of senior researchers and PhD's at Brainclinics. Dr. Arns collaborates with many international colleagues and published more than 100 scientific publications. Dr. Arns is also affiliated with Utrecht University, department of experimental psychology. In 2006 he founded Psychology Practice Brainclinics where new innovative treatments (rTMS, Neurofeedback) and assessments (sleep, QEEG) were pioneered and validated. In 2015 the Psychology Practice Brainclinics was acquired by the neuroCare Group and he serves as an adviser for protocols and assessments developed for neuroCare Clinics worldwide.
Mitchell Belgin, RDMS
For 25 years, Mitchell Belgin, RDMS (Registered Diagnostic Medical Sonographer) was the principal owner of Sight of Sound Diagnostics echocardiographic and ultrasound diagnostic service, serving multiple cardiology practices in Manhattan. He attained an MBA in decision analysis. With Dr. Menolascino, he co-anchored a monthly public radio show, The Deciding Mind.
For the past 7 years, he has been director of TMS services at Washington Square TMS, providing direct services to patients and training to our TMS clinicians/technologists. Lastly, he runs our EEG lab and is currently a board-eligible QEEG Diplomate.